Stocktoria
HUTCHMED (China) Ltd HCM
Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2006-05-19
HUTCHMED (China) Ltd financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $548.5M | $630.2M | $838.0M | $426.4M | $356.1M | $228.0M | $204.9M | $214.1M | $241.2M | $216.1M |
| R&D expense | $148.3M | $212.1M | $302.0M | $386.9M | $299.1M | $174.8M | $138.2M | $114.2M | $75.5M | $66.9M |
| Operating income | -$39.2M | -$43.7M | $18.4M | -$407.7M | -$328.3M | -$196.7M | -$146.4M | -$92.6M | -$53.4M | -$46.7M |
| Interest expense | — | — | $759,000 | $652,000 | $592,000 | $787,000 | $1.0M | $1.0M | $1.5M | $1.6M |
| Income tax | $63.6M | $7.2M | $4.5M | -$283,000 | $11.9M | $4.8M | $3.3M | $4.0M | $3.1M | $4.3M |
| Net income | $456.9M | $37.7M | $100.8M | -$360.8M | -$194.6M | -$125.7M | -$106.0M | -$74.8M | -$26.7M | $11.7M |
| EPS (diluted) | $0.52 | $0.04 | $0.12 | $-0.43 | $-0.25 | $-0.18 | $-0.16 | $-1.13 | $-0.43 | $0.02 |
| Operating cash flow | -$64.7M | $497,000 | $219.3M | -$268.6M | -$204.2M | -$62.1M | -$80.9M | -$32.8M | -$8.9M | -$9.6M |
| Free cash flow | -$78.8M | -$17.4M | $186.6M | -$305.3M | -$220.6M | -$70.0M | -$89.5M | -$39.2M | -$14.0M | -$13.9M |
| Cash & equivalents | $71.3M | $154.0M | $283.6M | $313.3M | $377.5M | $235.6M | $121.2M | $86.0M | $85.3M | $79.4M |
| Inventory | $41.1M | $50.4M | $50.3M | $56.7M | $35.8M | $19.8M | $16.2M | $12.3M | $11.8M | $12.8M |
| Total assets | $1.8B | $1.3B | $1.3B | $1.0B | $1.4B | $724.1M | $465.1M | $532.1M | $597.9M | $342.4M |
| Total liabilities | $501.8M | $502.3M | $536.4M | $392.6M | $333.1M | $205.2M | $152.2M | $119.9M | $113.0M | $138.4M |
| Shareholders' equity | $1.3B | $771.9M | $743.4M | $636.9M | $1.0B | $518.9M | $312.9M | $411.6M | $483.9M | $204.1M |
Growth · year-over-year · Revenue CAGR 10.9%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | -13.0% | -24.8% | +96.5% | +19.7% | +56.2% | +11.3% | -4.3% | -11.2% | +11.6% | +21.3% |
| Net income growth | +1111.0% | -62.6% | — | — | — | — | — | — | -328.6% | +46.4% |
| EPS growth | +1200.0% | -66.7% | — | — | — | — | — | — | -2250.0% | — |
| Free cash flow growth | — | -109.3% | — | — | — | — | — | — | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.